The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated ...

Cereals have natural resistance genes that can protect them from disease-causing fungi. However, certain fungi, such as powdery mildew, are known to ...

Repeat-doses of DeltEx™ Drug-Resistant Immunotherapy gamma-delta (γδ) T cells (DRI) nearly doubled median progression-free survival (mPFS) to ...

Company expects preliminary unaudited AUCATZYL® net product revenue of approximately $24 million for the fourth quarter of 2025 and approximately ...

The use of base editing to generate universal off-the-shelf CAR T cells induced durable remissions -- up to 36 months in one ...

Scientists now believe that Brazil has one of the overlooked and underexplored populations when it comes to longevity. As per ...

Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...

T-cell engagers (TCEs) have the most promising product profile across all deep B-cell depleting modalitiesCizutamig (BCMA TCE) positioned as first and best-in-class for autoimmune diseasesOver 60 ...

J&J successfully acquired Halda Therapeutics for $3.05bn integrating Halda’s RIPTAC platform into J&J’s oncology portfolio.

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its ...